Yuko Ishihara
Overview
Explore the profile of Yuko Ishihara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
350
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Uryu H, Mishima Y, Ishihara Y, Shirouchi Y, Yamauchi N, Hirano M, et al.
J Clin Exp Hematop
. 2024 Mar;
64(1):10-20.
PMID: 38538316
High-risk cytogenetic abnormalities (HRCAs) influence the prognosis of multiple myeloma (MM). However, additional cytogenetic aberrations can lead to poor outcomes. This study aimed to clarify whether HRCAs and additional chromosomal...
2.
Shirouchi Y, Nishimura N, Mishima Y, Ishihara Y, Asai H, Tamba M, et al.
Sci Rep
. 2023 Aug;
13(1):13713.
PMID: 37608029
Patients with DLBCL achieving complete metabolic response (CMR) after initial treatment with R-CHOP generally have a favourable prognosis; however, there are no established prognostic biomarkers for relapse in these patients....
3.
Munakata W, Izutsu K, Mishima Y, Nagai H, Ishihara Y, Suzumiya J, et al.
Jpn J Clin Oncol
. 2023 Jul;
53(10):912-921.
PMID: 37486002
Objective: This dose-escalation part of an ongoing Phase I study assessed the tolerability, safety and pharmacokinetics of mosunetuzumab in Japanese patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). Methods: Mosunetuzumab was...
4.
Shirouchi Y, Mishima Y, Takayama T, Minowa S, Ishihara Y, Tamba M, et al.
Biomed Res
. 2022 Aug;
43(4):99-106.
PMID: 35989290
Cell-free DNA (cfDNA) is a fragment of DNA circulating in the blood, and its concentration is often elevated in cancer patients. To investigate the relationships between serum cfDNA concentration and...
5.
Hayakawa J, Nakasone H, Minakata D, Fujiwara S, Gomyo A, Akahoshi Y, et al.
Int J Hematol
. 2022 Apr;
116(2):239-247.
PMID: 35429328
High-dose cytarabine (HD-AraC) or anthracycline-containing chemotherapies are used as post-remission therapy for acute myeloid leukemia (AML) patients. However, it remains unclear which regimen would be better as post-remission therapy before...
6.
Hirano M, Tamba M, Inoue N, Ikegami M, Onda N, Shirouchi Y, et al.
Ann Hematol
. 2022 Feb;
101(7):1587-1589.
PMID: 35187605
No abstract available.
7.
Kawamura K, Tanaka Y, Nakasone H, Ishihara Y, Kako S, Kobayashi S, et al.
Biol Blood Marrow Transplant
. 2020 Apr;
26(8):1377-1385.
PMID: 32311478
Adult T cell leukemia/lymphoma (ATL) is an aggressive peripheral T cell neoplasm caused by infection with human T cell lymphotropic virus type-1 (HTLV-1). Its prognosis remains extremely poor. Tax, the...
8.
Nishikawa K, Kimura K, Kanda Y, Sugiyama M, Kakihana K, Doki N, et al.
Bone Marrow Transplant
. 2020 Feb;
55(7):1388-1398.
PMID: 32071416
Hepatitis B virus (HBV) reactivation reportedly occurs frequently after hematopoietic stem cell transplantation (HSCT) in resolved HBV-infected patients. Here, 50 patients with resolved HBV infections and scheduled to undergo HSCT...
9.
Harada N, Kimura S, Gomyo A, Hayakawa J, Tamaki M, Akahoshi Y, et al.
J Infect Chemother
. 2019 Nov;
26(2):175-180.
PMID: 31735628
Objective: Although invasive fungal disease (IFD) is an important complication in allogeneic hematopoietic stem cell transplantation (HSCT), the clinical significance of surgery, including the role of surgical resection for persistent...
10.
Yamamoto C, Nakashima H, Ikeda T, Kawaguchi S, Toda Y, Ito S, et al.
Blood Adv
. 2019 Nov;
3(21):3266-3277.
PMID: 31698458
The cost of tyrosine kinase inhibitors (TKIs) in the treatment of chronic myeloid leukemia (CML) is a substantial economic burden. In Japan, imatinib, dasatinib, and nilotinib are now approved as...